At Emmecell, we are committed to curing blindness.  Our mission is to bring innovative regenerative medicine out of the  laboratory and into patient care.  

We are harnessing the power of our platform to discover and develop new cell-based therapies that have the
potential to transform the lives of patients with serious eye diseases. 

Product Pipeline

Clinical Trials

EO2002 - Magnetic Human Corneal Endothelial Cells for Corneal Edema

On September 17, 2020, the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application for EO2002, Emmecell’s lead product candidate for the treatment of corneal edema, enabling Emmecell to begin a Phase 1 clinical trial in the US. 

For more information about our clinical trials, visit www.clinicaltrials.gov or contact us at clinicaltrials@emmecell.com.